Restricted accessArticle commentaryFirst published online 2025-1
A Randomized Trial Evaluating Acceptance and Commitment Therapy and Smart Phone Care Management Application to Augment Buprenorphine Therapy for Opioid Use and Chronic Pain
There is high comorbidity of opioid use disorder (OUD) and chronic pain (CP), which is often addressed by prescribing buprenorphine (BUP). While BUP is effective in preventing overdose, it does not address the psychological aspects of OUD and CP comorbidity and treatment retention rates are as low as 50%. The Virtual Opioid use disorder Integrated Chronic Pain Treatment (VOICE) study (NCT05039554) is a novel effectiveness-implementation trial to test a 12-week virtual group Acceptance and Commitment Therapy (ACT) protocol and a care management smartphone application (app; Valera Health) on pain and opioid use in patients with OUD and CP receiving BUP. Using a 2 × 2 factorial design, participants (expected N = 280) are randomized into: ACT, Valera app, ACT + Valera, or Treatment as Usual arm. This study is taking place in the Bronx, NY, a racially/ethnically diverse community that faces numerous socioeconomic stressors and is one of the nation’s epicenters of the opioid epidemic. We created a culturally responsive ACT group protocol, and Valera psychoeducational material. Outcome measures include NIH HEAL Common Data Elements and ACT and Valera-specific measures. We are conducting a novel 2 × 2 trial investigating augmenting BUP treatment with ACT and Valera, with the goal that improved mental health and access to care will result in decreased and opioid use and pain interference.
DelormeJKerckhoveNAuthierNPereiraBBertinCChenafC.Systematic review and meta-analysis of the prevalence of chronic pain among patients with opioid use disorder and receiving opioid substitution therapy. J Pain. 2023;24(2):192-203. doi:10.1016/j.jpain.2022.08.008
2.
MacleanRRSofuogluMStefanovicsERosenheckR.Opioid use disorder with chronic pain increases disease burden and service use. Psychol Serv. 2023;20(1):157-165. doi:10.1037/ser0000607
3.
FinchJWKamienJBAmassL.Two-year experience with buprenorphine-naloxone (suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addict Med. 2007;1(2):104-110. doi:10.1097/adm.0b013e31809b5df2
4.
GhabrashMFBahremandAVeilleuxM, et al. Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: a literature review. J Dual Diagn. 2020;16(2):191-207. doi:10.1080/15504263.2020.1726549
5.
SteinMDHermanDSKettavongM, et al. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010;39(2):157-166. doi:10.1016/j.jsat.2010.05.014
6.
AaronRVFinanPHWegenerSTKeefeFJLumleyMA.Emotion regulation as a transdiagnostic factor underlying co-occurring chronic pain and problematic opioid use. Am Psychol. 2020;75(6):796-810. doi:10.1037/amp0000678
7.
BenningfieldMMArriaAMKaltenbachK, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010;19(5):416-421. doi:10.1111/j.1521-0391.2010.00064.x
8.
CharneyDAPalacios-BoixJNegreteJCDobkinPLGillKJ.Association between concurrent depression and anxiety and six-month outcome of addiction treatment. Psychiatr Serv. 2005;56(8):927-933. doi:10.1176/appi.ps.56.8.927
9.
FischAPatchVDGreenfieldARaynesAEMcKennaGLevineM.Depression and self-concept as variables in the differential response to methadone maintenance combined with therapy. Proc Natl Conf Methadone Treat. 1973;1:440-446.
10.
ManchikantiMLGiordanoPJBoswellMPMVFellowsMBManchukondaBRPampatiMV.Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag. 2007;3(2):89-100. doi:10.5055/jom.2007.0045
11.
HayesSCWilsonKGGiffordEV, et al. A preliminary trial of twelve-step facilitation and acceptance and commitment therapy with polysubstance-abusing methadone-maintained opiate addicts. Behav Ther. 2004;35(4):667-688. doi:10.1016/s0005-7894(04)80014-5
12.
StottsALGreenCMasudaA, et al. A Stage I pilot study of acceptance and commitment therapy for methadone detoxification. Drug Alcohol Depend. 2012;125(3):215-222. doi:10.1016/j.drugalcdep.2012.02.015
13.
BarryDTBeitelMCutterCJ, et al. Allopathic, complementary, and alternative medical treatment utilization for pain among methadone-maintained patients. Am J Addict. 2009;18(5):379-385. doi:10.3109/10550490903077671
14.
BeitelMOberleitnerLKahnM, et al. Drug counselor responses to patients’ pain reports: a qualitative investigation of barriers and facilitators to treating patients with chronic pain in methadone maintenance treatment. Pain Med. 2017;18(11):2152-2161. doi:10.1093/pm/pnw327
15.
KhannaSGreesonJM.A narrative review of yoga and mindfulness as complementary therapies for addiction. Complement Ther Med. 2013;21(3):244-252. doi:10.1016/j.ctim.2013.01.008
16.
NambiGShanmugananth DeviSInbasekaranDJagannathanKKhumanR.Changes in pain intensity and health related quality of life with Iyengar yoga in nonspecific chronic low back pain: a randomized controlled study. Int J Yoga. 2014;7(1):48-53. doi:10.4103/0973-6131.123481
17.
DahlJWilsonKGNilssonA.Acceptance and commitment therapy and the treatment of persons at risk for long-term disability resulting from stress and pain symptoms: a preliminary randomized trial. Behav Ther. 2004;35(4):785-801. doi:10.1016/s0005-7894(04)80020-0
18.
McCrackenLMVowlesKEEcclestonC.Acceptance-based treatment for persons with complex, long standing chronic pain: a preliminary analysis of treatment outcome in comparison to a waiting phase. Behav Res Ther. 2005;43(10):1335-1346. doi:10.1016/j.brat.2004.10.003
19.
McCrackenLMVellemanSC.Psychological flexibility in adults with chronic pain: a study of acceptance, mindfulness, and values-based action in primary care. Pain. 2010;148(1):141-147. doi:10.1016/j.pain.2009.10.034
20.
McCrackenLMVowlesKE.Acceptance and commitment therapy and mindfulness for chronic pain: model, process, and progress. Am Psychol. 2014;69(2):178-187. doi:10.1037/a0035623
21.
WicksellRKAhlqvistJBringAMelinLOlssonGL.Can exposure and acceptance strategies improve functioning and life satisfaction in people with chronic pain and Whiplash-associated disorders (WAD)? A randomized controlled trial. Cogn Behav Ther. 2008;37(3):169-182. doi:10.1080/16506070802078970
22.
BatchelderAWBrisbaneMLitwinAHNahviSBergKMArnstenJH.“Damaging what wasn’t damaged already”: psychological tension and antiretroviral adherence among HIV-infected methadone-maintained drug users. AIDS Care. 2013;25(11):1370-1374. doi:10.1080/09540121.2013.766303
23.
ManceGARodgersCRRRobertsDTerryA.Deeply rooted: maximizing the strengths of a historically black university and community-based participatory research to understand environmental stressors and trauma among black youth. Am J Community Psychol. 2020;66(3-4):256-266. doi:10.1002/ajcp.12452
24.
AlderksCE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). In: The CBHSQ Report. Substance Abuse and Mental Health Services Administration (US); 2013:1-8.
25.
BergKMLitwinALiXHeoMArnstenJH.Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113(2-3):192-199. doi:10.1016/j.drugalcdep.2010.07.025
26.
IlgenMABohnertASBChermackS, et al. A randomized trial of a pain management intervention for adults receiving substance use disorder treatment. Addiction. 2016;111(8):1385-1393. doi:10.1111/add.13349
27.
MurphyKRHanJLYangS, et al. Prevalence of specific types of pain diagnoses in a sample of United States adults. Pain Physician. 2017;20(2):E257-E268.
28.
MugandaPC.County Health Rankings & Roadmaps. University of Wisconsin Population Health Institute; 2022.
CarletonKEPatelUBSteinDMouDMallowABlackmoreMA.Enhancing the scalability of the collaborative care model for depression using mobile technology. Transl Behav Med. 2020;10(3):573-579. doi:10.1093/tbm/ibz146
31.
University of Wisconsin Population Health Institute. County Health Rankings & Roadmaps. University of Wisconsin Population Health Institute; 2023.
32.
AllenBNolanMLKuninsHVPaoneD.Racial differences in opioid overdose deaths in New York City, 2017. JAMA Intern Med. 2019;179(4):576-578. doi:10.1001/jamainternmed.2018.7700
33.
NYC Department of Health. Epi Data Briefs and Data Tables. NYC Department of Health; 2023.
34.
CunninghamCGiovannielloASacajiuG, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40(7):500-506.
35.
CunninghamCOGiovannielloASacajiuGLiXBrisbaneMSohlerNL.Inquiries about and initiation of buprenorphine treatment in an inner-city clinic. Subst Abuse. 2009;30(3):261-262. doi:10.1080/08897070903041301
36.
CunninghamCOGiovannielloAKuninsHVRooseRJFoxADSohlerNL.Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict. 2013;22(4):352-357. doi:10.1111/j.1521-0391.2013.12032.x
37.
CunninghamCOKhalidLDengY, et al. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. J Subst Abuse Treat. 2022;135:108641. doi:10.1016/j.jsat.2021.108641
38.
JakubowskiALuTDirennoF, et al. Same-day vs. Delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program. J Subst Abuse Treat. 2020;119:108140. doi:10.1016/j.jsat.2020.108140
39.
KhalidLCunninghamCODengY, et al. Cascade of care for office-based buprenorphine treatment in Bronx community clinics. J Subst Abuse Treat. 2022;139:108778. doi:10.1016/j.jsat.2022.108778
KrebsEELorenzKABairMJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733-738. doi:10.1007/s11606-009-0981-1
42.
BhambhaniYGalloL.Persisting with purpose: an acceptance and commitment therapy group treatment manual for comorbid opioid use disorder and chronic pain. Manuscript under review, 2024.
43.
National Institute on Drug Abuse. Drug Overdose Death Rates. National Institute on Drug Abuse; 2023.
44.
CarlsonRGNahhasRWMartinsSSDaniulaityteR.Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alcohol Depend. 2016;160:127-134. doi:10.1016/j.drugalcdep.2015.12.026
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
